EA200800784A1 - Пиридиновые производные и их применение для лечения психотических расстройств - Google Patents
Пиридиновые производные и их применение для лечения психотических расстройствInfo
- Publication number
- EA200800784A1 EA200800784A1 EA200800784A EA200800784A EA200800784A1 EA 200800784 A1 EA200800784 A1 EA 200800784A1 EA 200800784 A EA200800784 A EA 200800784A EA 200800784 A EA200800784 A EA 200800784A EA 200800784 A1 EA200800784 A1 EA 200800784A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- 6alkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
В соответствии с настоящим изобретением обеспечиваются новые соединения формулы (I) или их фармацевтически приемлемые соли, где Х представляет собой атом азота; Y представляет собой -С(Н)-, (-С(Н)-), -S(O)- или -С(=O)-; Z представляет собой -С(Н)-, -S(O)-, -N(R)- или атом кислорода или серы; А представляет собой водород или -CHOH; Rпредставляет собой водород, Cалкил, Cалкокси, -CORили -SOR; Rпредставляет собой галоген, Cалкил, Cалкокси, =O, галогенСалкил или галогенСалкокси, гидроксил или -CHOH; m представляет собой целое число, имеющее значение от 0 до 3; Rпредставляет собой галоген, =О, Cалкил (необязательно замещенный одной или несколькими гидроксильными группами), -COOR, -CONRR, Cалкокси, галогенCалкил, галогенСалкокси или СалкилСалкил; n представляет собой целое число, имеющее значение от 0 до 3; р и q независимо представляют собой целое число, имеющее значение от 0 до 2; Rпредставляет собой группу -арил, -гетероарил, -гетероциклил, -арил-арил, -арил-гетероарил, -арил-гетероциклил, -гетероарил-арил, -гетероарил-гетероарил, -гетероарил-гетероциклил, -гетероциклил-арил, гетероциклил-гетероарил или -гетероциклил-гетероциклил, все из которых, необязательно, могут быть замещены одной или несколькими группами (например, 1, 2 или 3 группами) галоген, Cалкил, Сциклоалкил, Cалкокси, гидроксил, галогенСалкил, галогенСалкокси, циано, -S-Cалкил, -SO-Cалкил, -SO-Cалкил, -COR, -CONRR, -NRR, NRCOCалкил, NRSO-Cалкил, Cалкил-NRR, -OCONRR, -NRCORили -SONRR; Rи Rнезависимо представляют собой Cалкил, или Rи Rвместе с атомом углерода, с которым они связаны, вместе могут образовывать Сциклоалкильную группу; Rпредставляет собой галоген, Cалкил, Сциклоалкил, Cалкокси, галогенCалкил или галогенСалкокси; s представляет собой целое число, имеющее значение от 0 до 4; Rи Rнезависимо представляют собой водород, Cалкил или Сциклоалкил; или их сольваты.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0518472A GB0518472D0 (en) | 2005-09-09 | 2005-09-09 | Novel compounds |
GB0611153A GB0611153D0 (en) | 2006-06-06 | 2006-06-06 | Novel compounds |
PCT/EP2006/008845 WO2007028654A1 (en) | 2005-09-09 | 2006-09-07 | Pyridine derivatives and their use in the treatment of psychotic disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200800784A1 true EA200800784A1 (ru) | 2008-06-30 |
EA013909B1 EA013909B1 (ru) | 2010-08-30 |
Family
ID=37546936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800784A EA013909B1 (ru) | 2005-09-09 | 2006-09-07 | Пиридиновые производные и их применение для лечения психотических расстройств |
Country Status (27)
Country | Link |
---|---|
US (3) | US7683056B2 (ru) |
EP (2) | EP1928886B1 (ru) |
JP (1) | JP5121716B2 (ru) |
KR (1) | KR101292348B1 (ru) |
AR (1) | AR058805A1 (ru) |
AT (1) | ATE505472T1 (ru) |
AU (1) | AU2006289281B2 (ru) |
BR (1) | BRPI0615787B8 (ru) |
CA (1) | CA2621564C (ru) |
CR (1) | CR9847A (ru) |
CY (1) | CY1111907T1 (ru) |
DE (1) | DE602006021323D1 (ru) |
DK (1) | DK1928886T3 (ru) |
EA (1) | EA013909B1 (ru) |
HR (1) | HRP20110457T1 (ru) |
IL (1) | IL189578A (ru) |
JO (1) | JO2722B1 (ru) |
MA (1) | MA29780B1 (ru) |
MY (1) | MY145713A (ru) |
NO (1) | NO340921B1 (ru) |
NZ (1) | NZ565983A (ru) |
PE (1) | PE20070614A1 (ru) |
PL (1) | PL1928886T3 (ru) |
PT (1) | PT1928886E (ru) |
SI (1) | SI1928886T1 (ru) |
TW (1) | TWI378101B (ru) |
WO (1) | WO2007028654A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
JP5139307B2 (ja) * | 2005-10-10 | 2013-02-06 | グラクソ グループ リミテッド | ナトリウムチャネルモジュレーターとしてのプロリンアミド誘導体 |
SI2404919T1 (sl) | 2005-11-08 | 2013-12-31 | Vertex Pharmaceuticals Incorporated | Heterocikliäśna spojina uporabna kot modulator za prenaĺ alce z atp-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
KR20150063170A (ko) | 2007-12-07 | 2015-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
DK2639222T3 (en) | 2007-12-07 | 2016-10-03 | Vertex Pharma | Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer |
PL2098526T3 (pl) * | 2008-02-22 | 2014-06-30 | Neurotune Ag | Bicykliczne związki zawierające azot aktywne w stanach przewlekłego bólu |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
FR2928150A1 (fr) | 2008-02-29 | 2009-09-04 | Vetoquinol Sa Sa | Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens |
WO2009119528A1 (ja) * | 2008-03-24 | 2009-10-01 | 武田薬品工業株式会社 | 複素環化合物 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
EP2145891A1 (en) | 2008-07-09 | 2010-01-20 | Vetoquinol S.A. | 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials |
GB0814340D0 (en) * | 2008-08-05 | 2008-09-10 | Smithkline Beecham Corp | Anhydrous crystol form fo a pyridine derivative |
TW201109335A (en) | 2009-08-04 | 2011-03-16 | Takeda Pharmaceutical | Heterocyclic compounds |
AU2010288502B2 (en) * | 2009-08-27 | 2013-12-12 | KaNDy Therapeutics Ltd. | Anhydrate forms of a pyridine derivative |
WO2011054773A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Novel lactam compounds |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
US9115132B2 (en) | 2010-07-09 | 2015-08-25 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
UY34349A (es) | 2011-09-29 | 2013-04-05 | Abb Vie Inc | OCTAHIDROPIRROLO[1,2-a]PIRAZINA SULFONAMIDAS SUSTITUIDAS COMO BLOQUEADORES DE CANALES DE CALCIO |
WO2013049164A1 (en) * | 2011-09-29 | 2013-04-04 | Abbvie Inc. | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS |
WO2014093337A1 (en) | 2012-12-12 | 2014-06-19 | Abbvie, Inc. | Diazepine derivatives useful as calcium channel blockers in the treatment of pain |
US10100030B2 (en) | 2013-11-08 | 2018-10-16 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
ES2865600T3 (es) | 2013-11-12 | 2021-10-15 | Vertex Pharma | Proceso de preparación de composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
JP6609253B2 (ja) * | 2014-08-06 | 2019-11-20 | キッセイ薬品工業株式会社 | シアノチオフェン誘導体 |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
US10421716B2 (en) | 2014-12-23 | 2019-09-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide pyrrolidine derivatives |
MX2017012720A (es) * | 2015-05-18 | 2018-02-09 | Nerre Therapeutics Ltd | Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales. |
WO2019071162A2 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
BR112020017388A2 (pt) | 2018-03-14 | 2020-12-15 | KaNDy Therapeutics Limited | Formulação farmacêutica compreendendo antagonistas duplos dos receptores nk-1/nk-3 |
US11583538B2 (en) | 2019-04-08 | 2023-02-21 | Venenum Biodesign, LLC | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors |
EP4058433A1 (en) | 2019-11-15 | 2022-09-21 | KaNDy Therapeutics Limited | New chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of nt-814 |
WO2021261969A1 (ko) * | 2020-06-26 | 2021-12-30 | 홀로스메딕 주식회사 | 신규한 화합물의 제조방법 |
WO2022075974A1 (en) * | 2020-10-06 | 2022-04-14 | Venenum Biodesign, LLC | Cyclic trex1 inhibitors |
EP4319735A1 (en) * | 2021-04-05 | 2024-02-14 | The Board of Trustees of the Leland Stanford Junior University | Enantiomer selective action on neurotransmission |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4921855A (en) | 1987-06-22 | 1990-05-01 | Fujisawa Pharmaceutical Co., Ltd. | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same |
US5166203A (en) | 1990-08-30 | 1992-11-24 | Kanebo, Ltd. | Quinolinecarboxylic acid derivatives, antibacterial agent containing the same |
EP1486498A1 (en) | 1998-11-23 | 2004-12-15 | Pfizer Products Inc. | Process and intermediates for growth hormone secretagogues |
SE1035115T5 (sv) | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
DOP2000000107A (es) | 1999-12-01 | 2002-09-16 | Agouron Pharmaceutical Inc | Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas |
TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203020D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
TW200407324A (en) | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
DE602004008631T2 (de) | 2003-07-03 | 2008-07-10 | F. Hoffmann-La Roche Ag | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie |
-
2006
- 2006-09-07 EP EP06777183A patent/EP1928886B1/en active Active
- 2006-09-07 JO JO2006301A patent/JO2722B1/en active
- 2006-09-07 TW TW095132989A patent/TWI378101B/zh active
- 2006-09-07 DE DE602006021323T patent/DE602006021323D1/de active Active
- 2006-09-07 CA CA2621564A patent/CA2621564C/en active Active
- 2006-09-07 PL PL06777183T patent/PL1928886T3/pl unknown
- 2006-09-07 AR ARP060103894A patent/AR058805A1/es active IP Right Grant
- 2006-09-07 EP EP10190918A patent/EP2336136A1/en not_active Withdrawn
- 2006-09-07 MY MYPI20064110A patent/MY145713A/en unknown
- 2006-09-07 KR KR1020087008441A patent/KR101292348B1/ko active IP Right Grant
- 2006-09-07 WO PCT/EP2006/008845 patent/WO2007028654A1/en active Application Filing
- 2006-09-07 NZ NZ565983A patent/NZ565983A/en not_active IP Right Cessation
- 2006-09-07 SI SI200631047T patent/SI1928886T1/sl unknown
- 2006-09-07 DK DK06777183.2T patent/DK1928886T3/da active
- 2006-09-07 EA EA200800784A patent/EA013909B1/ru unknown
- 2006-09-07 PE PE2006001077A patent/PE20070614A1/es not_active Application Discontinuation
- 2006-09-07 JP JP2008529564A patent/JP5121716B2/ja active Active
- 2006-09-07 BR BRPI0615787A patent/BRPI0615787B8/pt active IP Right Grant
- 2006-09-07 PT PT06777183T patent/PT1928886E/pt unknown
- 2006-09-07 AT AT06777183T patent/ATE505472T1/de active
- 2006-09-07 AU AU2006289281A patent/AU2006289281B2/en active Active
- 2006-09-07 US US12/065,923 patent/US7683056B2/en active Active
-
2008
- 2008-02-18 IL IL189578A patent/IL189578A/en active IP Right Grant
- 2008-03-17 MA MA30749A patent/MA29780B1/fr unknown
- 2008-03-28 CR CR9847A patent/CR9847A/es not_active Application Discontinuation
- 2008-04-07 NO NO20081728A patent/NO340921B1/no unknown
-
2009
- 2009-12-14 US US12/636,849 patent/US7919491B2/en active Active
-
2011
- 2011-02-23 US US13/032,740 patent/US8097618B2/en active Active
- 2011-06-17 HR HR20110457T patent/HRP20110457T1/hr unknown
- 2011-07-04 CY CY20111100641T patent/CY1111907T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200800784A1 (ru) | Пиридиновые производные и их применение для лечения психотических расстройств | |
ATE439129T1 (de) | Verwendung von crth2-antagonisten-verbindungen in der therapie | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
CY1117165T1 (el) | Καινοφανεις τρικυκλικες ενωσεις | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
CY1117085T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
ATE478058T3 (de) | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung | |
PA8621901A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CY1112941T1 (el) | Δικυκλικοι αναστολεις της μεκ | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
EA200700099A1 (ru) | Производные пиридина | |
ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
NO20054880L (no) | Azaspiroalkanderivater som inhibitorer av metallproeaser | |
EA200000700A3 (ru) | НОВЫЕ β- КАРБОЛИНОВЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИХ | |
EA200701780A1 (ru) | Противоопухолевое средство | |
NI200400073A (es) | Compuestos de fenilsulfonamida sustituida inhibidores de la produccion de beta-amiloide | |
DK2125736T3 (da) | Substituerede acetophenoner egnede som PDE4-inhibitorer | |
CY1111517T1 (el) | Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης | |
HN2005000239A (es) | Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica | |
RS53613B1 (en) | COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC4A | Registration of transfer of a eurasian patent by assignment | ||
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
PC4A | Registration of transfer of a eurasian patent by assignment |